When a company such as Lipocine conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the LPCN split history from start to finish, an original position size of 1000 shares would have turned into 58.8235294117647 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lipocine shares, starting with a $10,000 purchase of LPCN, presented on a split-history-adjusted basis factoring in the complete LPCN split history.

About Lipocine

Lipocine is clinical-stage biopharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. Co. has a license agreement for the development and commercialization its product candidate, TLANDO®, an oral testosterone replacement therapy comprised of testosterone undecanoate. Co.'s additional pipeline candidates, LPCN 1148 comprising a prodrug of testosterone, testosterone laurate, for the management of decompensated cirrhosis. Co. is conducting a Phase 2 POC study in male cirrhotic subjects to evaluate the therapeutic potential of LPCN 1148 for the management of sarcopenia. According to our LPCN split history records, Lipocine has had 1 split.

LPCN Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved